Bioverativ is Initiated by Raymond James to “Strong Buy”

Bioverativ (BIVV) was Initiated by Raymond James to “Strong Buy” and the brokerage firm has set the Price Target at $59. Raymond James advised their Clients and Investors in a research report released on Feb 7, 2017.

Bioverativ

Leave a Reply

Bioverativ - Is it time to Sell?

Top Brokerage Firms are advising their investors on Bioverativ. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.